Project investigating the question of whether pregnant women ar more likely to contract COVID-19, and at a higher risk of severe disease, complications and hospitalizations than non-pregnant women of reproductive age.
Personalised medicine is an important priority area for the Nordic co-operation in medical research. Nordic universities have now joined forces to set up a massive open online course (MOOC) targeting personalised medicine where medical experts from the Nordic countries have contributed.
Five proposals for activities aiming to promote Nordic clinical research cooperation related to international activities have been granted support from the Nordic Trial Alliance at NordForsk.
The Nordic and Japanese populations are getting older and challenging the health care systems. How do we ensure a healthy ageing for the individual? Researchers from the Nordic countries in collaboration with Japan will investigate this in three new research projects
The success of this project may enable the development of actionable, personalised interventional strategies to slow down ageing and prevent/delay age-predisposed diseases.
This project will identify people at-risk of dementia who may benefit from preventive interventions and investigate biological mechanisms for the development and prevention of dementia including between country comparisons of the Nordics and Japan.
This project envisions the development of refined diagnostic approaches that identify Osteoarthritis subtypes and indicators of its progression, at earlier stages of the disease.
Acute myelogenous leukemia (AML) is the most coomon acute leukemia in adults with and annual incidence of 4 cases per 100 000 inhabitans. Median age at diagnosis is 70 years. For patients below 55 years, the prognosis has gradually improved the last decades, but elderly patiens still do poorly; the survival being around 30% with no improvement of outome after standard chemotherapy treatment.
Crohn's disease is a chronic inflammatory bowel disease. The biological drug Remicade is used in patients with Crohn's disease when normal treatment is inadequate. About one in three of the patients starting treatment with Remicade have sustained good effect over several years. However, serious side effects such as; infections, allergic reactions and concerns about long-term safety, with suspected increased risk of developing cancer, necessitate exploring strategies for when and in which patients to stop (discontinue) treatment again.
